Fulcrum Therapeutics, Inc. (FULC) financial statements (2022 and earlier)

Company profile

Business Address 26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35,41257,05296,713
Cash and cash equivalents35,41257,05296,713
Receivables3,6372,531 
Other current assets 74284
Other undisclosed current assets186,94959,8533,086
Total current assets:225,998119,510100,083
Noncurrent Assets
Property, plant and equipment7,3688,3979,205
Restricted cash and investments1,0921,0921,092
Other noncurrent assets54257859
Total noncurrent assets:9,00210,06710,356
TOTAL ASSETS:235,000129,577110,439
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,7747,6725,785
Accounts payable4,7884,0792,186
Accrued liabilities9966651,360
Employee-related liabilities4,9902,9282,239
Deferred revenue4,71114,9103,989
Other liabilities743849
Other undisclosed current liabilities3,6404,1052,317
Total current liabilities:19,19926,72512,140
Noncurrent Liabilities
Liabilities, other than long-term debt1,6804,6207,625
Deferred revenue 2,9716,011
Deferred rent credit1,6801,6491,559
Other liabilities  55
Other undisclosed noncurrent liabilities2,5823,0513,521
Total noncurrent liabilities:4,2627,67111,146
Total liabilities:23,46134,39623,286
Stockholders' equity
Stockholders' equity attributable to parent211,53995,18187,153
Common stock412823
Additional paid in capital514,362316,775237,931
Accumulated other comprehensive loss(397)(2) 
Accumulated deficit(302,467)(221,620)(150,801)
Total stockholders' equity:211,53995,18187,153
TOTAL LIABILITIES AND EQUITY:235,000129,577110,439

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Revenues19,1638,823 
Gross profit:19,1638,823 
Operating expenses(100,217)(80,434)(84,217)
Operating loss:(81,054)(71,611)(84,217)
Nonoperating income
(Other Nonoperating income)
  29
Loss before gain (loss) on sale of properties:(81,054)(71,611)(84,188)
Other undisclosed net income2077921,511
Net loss attributable to parent:(80,847)(70,819)(82,677)
Preferred stock dividends and other adjustments  (7,128)
Net loss available to common stockholders, diluted:(80,847)(70,819)(89,805)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(80,847)(70,819)(82,677)
Other comprehensive loss(395)(2) 
Comprehensive loss, net of tax, attributable to parent:(81,242)(70,821)(82,677)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: